Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study

Table 3 Clinical outcomes by randomized treatment during ACCORD-lipid trial, ACCORDION and full follow-up period

Event	During ACCORD-lipid (short-term effect)			P	Post-trial only (legacy effect)			P	Full follow-up (long-term effect)			P
	Rate of events (100 person-years)		Hazard Ratio (95% CI)		Rate of events (100 person-years)		Hazard ratio (95% CI)		Rate of events (100 person-years)		Hazard ratio (95% CI)
	Fibrate	Placebo	Hazard Ratio (95% CI)		Fibrate	Placebo	Hazard ratio (95% CI)		Fibrate	Placebo	Hazard ratio (95% CI)
All-cause mortality	1.54	2.26	0.68 (0.44, 1.04)	0.07	3.05	4.43	0.65 (0.45, 0.94)	0.02	2.23	3.24	0.68 (0.52, 0.88)	< 0.01
CVD mortality	0.67	1.28	0.53 (0.29, 0.98)	0.04	1.12	1.53	0.77 (0.43, 1.39)	0.38	0.88	1.39	0.63 (0.42, 0.95)	0.03
Nonfatal MI	1.76	2.45	0.72 (0.47, 1.09)	0.12	0.85	1.07	0.74 (0.33, 1.66)	0.47	1.40	1.91	0.74 (0.51, 1.06)	0.10
Stroke	0.56	0.74	0.75 (0.36, 1.56)	0.44	0.56	0.55	0.87 (0.33, 2.29)	0.78	0.58	0.67	0.88 (0.5, 1.56)	0.66
CHF	1.39	1.51	0.90 (0.55, 1.47)	0.68	0.65	0.93	0.69 (0.30, 1.57)	0.38	1.07	1.27	0.82 (0.54, 1.24)	0.35
Major CHD	3.01	4.60	0.65 (0.48, 0.90)	0.01	2.17	3.27	0.64 (0.40, 1.03)	0.07	2.67	4.09	0.66 (0.51, 0.86)	< 0.01

MI myocardial infarction, CHF congestive heart failure, CHD coronary heart disease